Reports / Anti-tuberculosis Therapeutics Market

Anti-tuberculosis Therapeutics Market

Anti-tuberculosis Therapeutics Market Research Report – Segmented By Drug Class (Amynoglycosides, Bedaquiline, Cyclic Peptides, Ethambutol, Fluoroquinolones, Isoniazid, Other Drug Classes, Pyrazinamide, Rifampin, Thioamides), End User (Government Agencies, Hospitals and Clinics, Non Profit Organizations, Other End Users) & Region (North America, Europe, APAC, Latin America, Middle East and Africa) – Analysis on Size, Share, Trends, COVID-19 Impact, Competitive Analysis, Growth Opportunities and Key Insights from 2017 to 2026.

Executive Summary

Anti-tuberculosis Therapeutics Market Size (2019 - 2027), USD million

Report Metric	Details
Market size available for years	2012-2027
Base year considered	2021
Forecast period	2022-2027
Forecast units	Value (USD Billion)
Segments covered	Drug Class, End User
Geographies covered	North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Companies Covered	Lupin Limited, Macleods Pharmaceuticals Ltd, Otsuka Pharmaceutical Co. Ltd, Johnson and Johnson, Pfizer Inc., Novartis AG

Anti-tuberculosis Therapeutics Market was valued at US $1,344.85 million in 2021 and is projected to grow at 6.21% CAGR over the forecast period to reach US $1,930.02 million by 2027. Anti-tuberculosis Therapeutics Market represented US $152.57 million opportunity over 2019-2021 and estimated to create US $585.17 million opportunity in 2027 over 2021.

Anti-tuberculosis Therapeutics from Consainsights analyses the Anti-tuberculosis Therapeutics Market in the Life Sciences industry over the forecast period to 2027.

Anti-tuberculosis Therapeutics research report from Consainsights outlines the detailed strategic analysis, trends, market opportunities, growth prospects, industry and market challenges and sustainable solutions to sustain in the competitive environment.

Anti-tuberculosis Therapeutics segmentation includes Drug Class, End User and Geography.

Based on the Drug Class, the Anti-tuberculosis Therapeutics analysis covers Isoniazid, Rifampin, Ethambutol, Pyrazinamide, Fluoroquinolones, Bedaquiline, Amynoglycosides, Thioamides, Cyclic Peptides, Other Drug Classes.

In Drug Class segment, Isoniazid segment has highest cagr growth of 5.50%.

Based on the End User, the Anti-tuberculosis Therapeutics analysis covers Hospitals and Clinics, Government Agencies, Non Profit Organizations, Other End Users.

In End User segment, Government Agencies segment has highest cagr growth of 5.50%.

Based on the region, the Anti-tuberculosis Therapeutics analysis covers North America, Europe, Asia-Pacific, Middle-East & Africa, Latin America.

Key companies operating in the market include Lupin Limited, Macleods Pharmaceuticals Ltd, Otsuka Pharmaceutical Co. Ltd, Johnson and Johnson, Pfizer Inc., Novartis AG and so on. This report covers the detailed analysis of the company profiles such as business segments, product portfolio, key brand insights and growth strategies adopted, company SWOT and Strategy analysis along with the financial analysis and analyst insights on the key companies operating in this market.

Revenue Share (%), By Drug Class (2021)
Revenue Share (%), By End User (2021)

Market Overview

The base currency considered was the US Dollar (USD). Conversion of other currencies to USD was considered on the basis of the average exchange rate for the respective review-period years. The exchange rate conversion for forecast period was determined according to the base year’s conversion rates.
The base year was identified based on the availability of annual reports and secondary information. The base year considered for this study is 2027.
The review period considered for this study is from 2018-2027. The CAGR is for the forecast period, 2022-2027.
Market size estimations for the forecast years were in real terms. Inflation is not part of the pricing, and the average selling price (ASP) was kept constant throughout the forecast period for each country.
Distribution of primary interviews conducted was based on the regional share of the market and the presence of key players in each region.
As a result of data triangulation through multiple methodologies and approaches, the weighted averages of resulting estimates were considered to be the final values.

The currency used in this report is USD, with the market size indicated in terms of USD million/billion.
For companies reporting their revenues in USD, the revenues were taken from their respective annual reports/SEC filings.
For companies reporting their revenues in other currencies, the average annual currency conversion rates were used for a particular year to convert the value to USD Market Definition.

By Drug Class

Isoniazid accounted for US$517.53 Bn in year 2021 and is expected to reach US$XX Bn in year 2027.
Rifampin accounted for US$321.98 Bn in year 2021 and is expected to reach US$XX Bn in year 2027.
Ethambutol accounted for US$203.00 Bn in year 2021 and is expected to reach US$XX Bn in year 2027.
Pyrazinamide accounted for US$125.65 Bn in year 2021 and is expected to reach US$XX Bn in year 2027.
Fluoroquinolones accounted for US$72.06 Bn in year 2021 and is expected to reach US$XX Bn in year 2027.
Bedaquiline accounted for US$42.19 Bn in year 2021 and is expected to reach US$XX Bn in year 2027.
Amynoglycosides accounted for US$24.72 Bn in year 2021 and is expected to reach US$XX Bn in year 2027.
Thioamides accounted for US$20.44 Bn in year 2021 and is expected to reach US$XX Bn in year 2027.
Cyclic Peptides accounted for US$8.85 Bn in year 2021 and is expected to reach US$XX Bn in year 2027.
Other Drug Classes accounted for US$8.43 Bn in year 2021 and is expected to reach US$XX Bn in year 2027.

Anti-tuberculosis Therapeutics Market Size, By Drug Class, 2019-2027 (USD million)

The Amynoglycosides segment market was valued at US$ XX Mn in 2019 and grown at XX% CAGR over the historic years (2019 - 2027) to reach US$ XX Mn and is projected to grow at XX% CAGR over the forecast period to reach US$ XX Mn by 2027. The market represented the US$ XX Mn opportunity over 2019 - 2027 and estimated to create US$ XX Mn opportunity over 2019 - 2027.

Amynoglycosides: global Anti-tuberculosis Therapeutics Market Revenue Opportunity (Us$ Mn)

The Bedaquiline segment market was valued at US$ XX Mn in 2019 and grown at XX% CAGR over the historic years (2019 - 2027) to reach US$ XX Mn and is projected to grow at XX% CAGR over the forecast period to reach US$ XX Mn by 2027. The market represented the US$ XX Mn opportunity over 2019 - 2027 and estimated to create US$ XX Mn opportunity over 2019 - 2027.

Bedaquiline: global Anti-tuberculosis Therapeutics Market Revenue Opportunity (Us$ Mn)

The Cyclic Peptides segment market was valued at US$ XX Mn in 2019 and grown at XX% CAGR over the historic years (2019 - 2027) to reach US$ XX Mn and is projected to grow at XX% CAGR over the forecast period to reach US$ XX Mn by 2027. The market represented the US$ XX Mn opportunity over 2019 - 2027 and estimated to create US$ XX Mn opportunity over 2019 - 2027.

Cyclic Peptides: global Anti-tuberculosis Therapeutics Market Revenue Opportunity (Us$ Mn)

The Ethambutol segment market was valued at US$ XX Mn in 2019 and grown at XX% CAGR over the historic years (2019 - 2027) to reach US$ XX Mn and is projected to grow at XX% CAGR over the forecast period to reach US$ XX Mn by 2027. The market represented the US$ XX Mn opportunity over 2019 - 2027 and estimated to create US$ XX Mn opportunity over 2019 - 2027.

Ethambutol: global Anti-tuberculosis Therapeutics Market Revenue Opportunity (Us$ Mn)

The Fluoroquinolones segment market was valued at US$ XX Mn in 2019 and grown at XX% CAGR over the historic years (2019 - 2027) to reach US$ XX Mn and is projected to grow at XX% CAGR over the forecast period to reach US$ XX Mn by 2027. The market represented the US$ XX Mn opportunity over 2019 - 2027 and estimated to create US$ XX Mn opportunity over 2019 - 2027.

Fluoroquinolones: global Anti-tuberculosis Therapeutics Market Revenue Opportunity (Us$ Mn)

The Isoniazid segment market was valued at US$ XX Mn in 2019 and grown at XX% CAGR over the historic years (2019 - 2027) to reach US$ XX Mn and is projected to grow at XX% CAGR over the forecast period to reach US$ XX Mn by 2027. The market represented the US$ XX Mn opportunity over 2019 - 2027 and estimated to create US$ XX Mn opportunity over 2019 - 2027.

Isoniazid: global Anti-tuberculosis Therapeutics Market Revenue Opportunity (Us$ Mn)

The Other Drug Classes segment market was valued at US$ XX Mn in 2019 and grown at XX% CAGR over the historic years (2019 - 2027) to reach US$ XX Mn and is projected to grow at XX% CAGR over the forecast period to reach US$ XX Mn by 2027. The market represented the US$ XX Mn opportunity over 2019 - 2027 and estimated to create US$ XX Mn opportunity over 2019 - 2027.

Other Drug Classes: global Anti-tuberculosis Therapeutics Market Revenue Opportunity (Us$ Mn)

The Pyrazinamide segment market was valued at US$ XX Mn in 2019 and grown at XX% CAGR over the historic years (2019 - 2027) to reach US$ XX Mn and is projected to grow at XX% CAGR over the forecast period to reach US$ XX Mn by 2027. The market represented the US$ XX Mn opportunity over 2019 - 2027 and estimated to create US$ XX Mn opportunity over 2019 - 2027.

Pyrazinamide: global Anti-tuberculosis Therapeutics Market Revenue Opportunity (Us$ Mn)

The Rifampin segment market was valued at US$ XX Mn in 2019 and grown at XX% CAGR over the historic years (2019 - 2027) to reach US$ XX Mn and is projected to grow at XX% CAGR over the forecast period to reach US$ XX Mn by 2027. The market represented the US$ XX Mn opportunity over 2019 - 2027 and estimated to create US$ XX Mn opportunity over 2019 - 2027.

Rifampin: global Anti-tuberculosis Therapeutics Market Revenue Opportunity (Us$ Mn)

The Thioamides segment market was valued at US$ XX Mn in 2019 and grown at XX% CAGR over the historic years (2019 - 2027) to reach US$ XX Mn and is projected to grow at XX% CAGR over the forecast period to reach US$ XX Mn by 2027. The market represented the US$ XX Mn opportunity over 2019 - 2027 and estimated to create US$ XX Mn opportunity over 2019 - 2027.

Thioamides: global Anti-tuberculosis Therapeutics Market Revenue Opportunity (Us$ Mn)

By End User

Hospitals and Clinics accounted for US$575.88 Bn in year 2021 and is expected to reach US$XX Bn in year 2027.
Government Agencies accounted for US$454.96 Bn in year 2021 and is expected to reach US$XX Bn in year 2027.
Non Profit Organizations accounted for US$130.95 Bn in year 2021 and is expected to reach US$XX Bn in year 2027.
Other End Users accounted for US$183.06 Bn in year 2021 and is expected to reach US$XX Bn in year 2027.

Anti-tuberculosis Therapeutics Market Size, By End User, 2019-2027 (USD million)

The Government Agencies segment market was valued at US$ XX Mn in 2019 and grown at XX% CAGR over the historic years (2019 - 2027) to reach US$ XX Mn and is projected to grow at XX% CAGR over the forecast period to reach US$ XX Mn by 2027. The market represented the US$ XX Mn opportunity over 2019 - 2027 and estimated to create US$ XX Mn opportunity over 2019 - 2027.

Government Agencies: global Anti-tuberculosis Therapeutics Market Revenue Opportunity (Us$ Mn)

The Hospitals and Clinics segment market was valued at US$ XX Mn in 2019 and grown at XX% CAGR over the historic years (2019 - 2027) to reach US$ XX Mn and is projected to grow at XX% CAGR over the forecast period to reach US$ XX Mn by 2027. The market represented the US$ XX Mn opportunity over 2019 - 2027 and estimated to create US$ XX Mn opportunity over 2019 - 2027.

Hospitals and Clinics: global Anti-tuberculosis Therapeutics Market Revenue Opportunity (Us$ Mn)

The Non Profit Organizations segment market was valued at US$ XX Mn in 2019 and grown at XX% CAGR over the historic years (2019 - 2027) to reach US$ XX Mn and is projected to grow at XX% CAGR over the forecast period to reach US$ XX Mn by 2027. The market represented the US$ XX Mn opportunity over 2019 - 2027 and estimated to create US$ XX Mn opportunity over 2019 - 2027.

Non Profit Organizations: global Anti-tuberculosis Therapeutics Market Revenue Opportunity (Us$ Mn)

The Other End Users segment market was valued at US$ XX Mn in 2019 and grown at XX% CAGR over the historic years (2019 - 2027) to reach US$ XX Mn and is projected to grow at XX% CAGR over the forecast period to reach US$ XX Mn by 2027. The market represented the US$ XX Mn opportunity over 2019 - 2027 and estimated to create US$ XX Mn opportunity over 2019 - 2027.

Other End Users: global Anti-tuberculosis Therapeutics Market Revenue Opportunity (Us$ Mn)

North America

In 2021, North America segment accounted for US$1344.85 Bn and is expected grow with a CAGR of 6.21% over the forecast years.
In North America, United States accounted for US$1137.28 Bn in year 2021 and is expected to reach US$XX Bn in year 2027.
Canada accounted for US$207.57 Bn in year 2021 and is expected to reach US$XX Bn in year 2027.

North America Anti-tuberculosis Therapeutics Market - Market Opportunity (USD million), 2019, 2021 & 2027

Revenue Share (%), By Drug Class - North America (2021)

Revenue Share (%), By End User - North America (2021)

United States Anti-tuberculosis Therapeutics Market - Historical, Forecast Market Sizes (US$ MN), By Drug Class, 2019-2027

United States Anti-tuberculosis Therapeutics Market - Historical, Forecast Market Sizes (US$ MN), By End User, 2019-2027

Canada Anti-tuberculosis Therapeutics Market - Historical, Forecast Market Sizes (US$ MN), By Drug Class, 2019-2027

Canada Anti-tuberculosis Therapeutics Market - Historical, Forecast Market Sizes (US$ MN), By End User, 2019-2027

Europe

In 2021, Europe segment accounted for US$1344.85 Bn and is expected grow with a CAGR of 6.21% over the forecast years.
In Europe, Germany accounted for US$509.43 Bn in year 2021 and is expected to reach US$XX Bn in year 2027.
United Kingdom accounted for US$328.99 Bn in year 2021 and is expected to reach US$XX Bn in year 2027.
France accounted for US$220.66 Bn in year 2021 and is expected to reach US$XX Bn in year 2027.
Spain accounted for US$128.05 Bn in year 2021 and is expected to reach US$XX Bn in year 2027.
Russia accounted for US$54.18 Bn in year 2021 and is expected to reach US$XX Bn in year 2027.
Italy accounted for US$72.94 Bn in year 2021 and is expected to reach US$XX Bn in year 2027.
Rest of Europe accounted for US$30.60 Bn in year 2021 and is expected to reach US$XX Bn in year 2027.

Europe Anti-tuberculosis Therapeutics Market - Market Opportunity (USD million), 2019, 2021 & 2027

Revenue Share (%), By Drug Class - Europe (2021)

Revenue Share (%), By End User - Europe (2021)

Germany Anti-tuberculosis Therapeutics Market - Historical, Forecast Market Sizes (US$ MN), By Drug Class, 2019-2027

Germany Anti-tuberculosis Therapeutics Market - Historical, Forecast Market Sizes (US$ MN), By End User, 2019-2027

United Kingdom Anti-tuberculosis Therapeutics Market - Historical, Forecast Market Sizes (US$ MN), By Drug Class, 2019-2027

United Kingdom Anti-tuberculosis Therapeutics Market - Historical, Forecast Market Sizes (US$ MN), By End User, 2019-2027

France Anti-tuberculosis Therapeutics Market - Historical, Forecast Market Sizes (US$ MN), By Drug Class, 2019-2027

France Anti-tuberculosis Therapeutics Market - Historical, Forecast Market Sizes (US$ MN), By End User, 2019-2027

Spain Anti-tuberculosis Therapeutics Market - Historical, Forecast Market Sizes (US$ MN), By Drug Class, 2019-2027

Spain Anti-tuberculosis Therapeutics Market - Historical, Forecast Market Sizes (US$ MN), By End User, 2019-2027

Russia Anti-tuberculosis Therapeutics Market - Historical, Forecast Market Sizes (US$ MN), By Drug Class, 2019-2027

Russia Anti-tuberculosis Therapeutics Market - Historical, Forecast Market Sizes (US$ MN), By End User, 2019-2027

Italy Anti-tuberculosis Therapeutics Market - Historical, Forecast Market Sizes (US$ MN), By Drug Class, 2019-2027

Italy Anti-tuberculosis Therapeutics Market - Historical, Forecast Market Sizes (US$ MN), By End User, 2019-2027

Rest of Europe Anti-tuberculosis Therapeutics Market - Historical, Forecast Market Sizes (US$ MN), By Drug Class, 2019-2027

Rest of Europe Anti-tuberculosis Therapeutics Market - Historical, Forecast Market Sizes (US$ MN), By End User, 2019-2027

Asia-Pacific

In 2021, Asia-Pacific segment accounted for US$1344.85 Bn and is expected grow with a CAGR of 6.21% over the forecast years.
In Asia-Pacific, China accounted for US$540.85 Bn in year 2021 and is expected to reach US$XX Bn in year 2027.
Japan accounted for US$341.42 Bn in year 2021 and is expected to reach US$XX Bn in year 2027.
India accounted for US$202.16 Bn in year 2021 and is expected to reach US$XX Bn in year 2027.
Southeast Asia accounted for US$140.39 Bn in year 2021 and is expected to reach US$XX Bn in year 2027.
Australia & New Zealand accounted for US$88.00 Bn in year 2021 and is expected to reach US$XX Bn in year 2027.
Rest of Asia-Pacific accounted for US$32.04 Bn in year 2021 and is expected to reach US$XX Bn in year 2027.

Asia-Pacific Anti-tuberculosis Therapeutics Market - Market Opportunity (USD million), 2019, 2021 & 2027

Revenue Share (%), By Drug Class - Asia-Pacific (2021)

Revenue Share (%), By End User - Asia-Pacific (2021)

China Anti-tuberculosis Therapeutics Market - Historical, Forecast Market Sizes (US$ MN), By Drug Class, 2019-2027

China Anti-tuberculosis Therapeutics Market - Historical, Forecast Market Sizes (US$ MN), By End User, 2019-2027

Japan Anti-tuberculosis Therapeutics Market - Historical, Forecast Market Sizes (US$ MN), By Drug Class, 2019-2027

Japan Anti-tuberculosis Therapeutics Market - Historical, Forecast Market Sizes (US$ MN), By End User, 2019-2027

India Anti-tuberculosis Therapeutics Market - Historical, Forecast Market Sizes (US$ MN), By Drug Class, 2019-2027

India Anti-tuberculosis Therapeutics Market - Historical, Forecast Market Sizes (US$ MN), By End User, 2019-2027

Southeast Asia Anti-tuberculosis Therapeutics Market - Historical, Forecast Market Sizes (US$ MN), By Drug Class, 2019-2027

Southeast Asia Anti-tuberculosis Therapeutics Market - Historical, Forecast Market Sizes (US$ MN), By End User, 2019-2027

Australia & New Zealand Anti-tuberculosis Therapeutics Market - Historical, Forecast Market Sizes (US$ MN), By Drug Class, 2019-2027

Australia & New Zealand Anti-tuberculosis Therapeutics Market - Historical, Forecast Market Sizes (US$ MN), By End User, 2019-2027

Rest of Asia-Pacific Anti-tuberculosis Therapeutics Market - Historical, Forecast Market Sizes (US$ MN), By Drug Class, 2019-2027

Rest of Asia-Pacific Anti-tuberculosis Therapeutics Market - Historical, Forecast Market Sizes (US$ MN), By End User, 2019-2027

Middle East & Africa

Based on the Middle East & Africa, the Anti-tuberculosis Therapeutics Market analysis covers Middle East, Africa, Rest of Middle East & Africa.

Middle East & Africa Anti-tuberculosis Therapeutics Size, 2019-2027 (Us$ Mn) — Middle East & Africa Anti-tuberculosis Therapeutics Market Size, 2019-2027 (Us$ Mn)

Middle East & Africa Anti-tuberculosis Therapeutics Market - Historical, Forecast Market Sizes (US$ MN), By Drug Class, 2019-2027

Middle East & Africa Anti-tuberculosis Therapeutics Market - Historical, Forecast Market Sizes (US$ MN), By End User, 2019-2027

Middle East Anti-tuberculosis Therapeutics Market - Historical, Forecast Market Sizes (US$ MN), By Drug Class, 2019-2027

Middle East Anti-tuberculosis Therapeutics Market - Historical, Forecast Market Sizes (US$ MN), By End User, 2019-2027

Africa Anti-tuberculosis Therapeutics Market - Historical, Forecast Market Sizes (US$ MN), By Drug Class, 2019-2027

Africa Anti-tuberculosis Therapeutics Market - Historical, Forecast Market Sizes (US$ MN), By End User, 2019-2027

Rest of Middle East & Africa Anti-tuberculosis Therapeutics Market - Historical, Forecast Market Sizes (US$ MN), By Drug Class, 2019-2027

Rest of Middle East & Africa Anti-tuberculosis Therapeutics Market - Historical, Forecast Market Sizes (US$ MN), By End User, 2019-2027

Latin America

In 2021, Latin America segment accounted for US$1344.85 Bn and is expected grow with a CAGR of 6.21% over the forecast years.
In Latin America, Brazil accounted for US$619.66 Bn in year 2021 and is expected to reach US$XX Bn in year 2027.
Argentina accounted for US$385.56 Bn in year 2021 and is expected to reach US$XX Bn in year 2027.
Mexico accounted for US$155.88 Bn in year 2021 and is expected to reach US$XX Bn in year 2027.
Colombia accounted for US$146.78 Bn in year 2021 and is expected to reach US$XX Bn in year 2027.
Rest of Latin America accounted for US$36.97 Bn in year 2021 and is expected to reach US$XX Bn in year 2027.

Latin America Anti-tuberculosis Therapeutics Market - Market Opportunity (USD million), 2019, 2021 & 2027

Revenue Share (%), By Drug Class - Latin America (2021)

Revenue Share (%), By End User - Latin America (2021)

Brazil Anti-tuberculosis Therapeutics Market - Historical, Forecast Market Sizes (US$ MN), By Drug Class, 2019-2027

Brazil Anti-tuberculosis Therapeutics Market - Historical, Forecast Market Sizes (US$ MN), By End User, 2019-2027

Argentina Anti-tuberculosis Therapeutics Market - Historical, Forecast Market Sizes (US$ MN), By Drug Class, 2019-2027

Argentina Anti-tuberculosis Therapeutics Market - Historical, Forecast Market Sizes (US$ MN), By End User, 2019-2027

Mexico Anti-tuberculosis Therapeutics Market - Historical, Forecast Market Sizes (US$ MN), By Drug Class, 2019-2027

Mexico Anti-tuberculosis Therapeutics Market - Historical, Forecast Market Sizes (US$ MN), By End User, 2019-2027

Colombia Anti-tuberculosis Therapeutics Market - Historical, Forecast Market Sizes (US$ MN), By Drug Class, 2019-2027

Colombia Anti-tuberculosis Therapeutics Market - Historical, Forecast Market Sizes (US$ MN), By End User, 2019-2027

Rest of Latin America Anti-tuberculosis Therapeutics Market - Historical, Forecast Market Sizes (US$ MN), By Drug Class, 2019-2027

Rest of Latin America Anti-tuberculosis Therapeutics Market - Historical, Forecast Market Sizes (US$ MN), By End User, 2019-2027

Company Analysis

Lupin Limited
Macleods Pharmaceuticals Ltd
Otsuka Pharmaceutical Co. Ltd
Johnson and Johnson
Pfizer Inc.
Novartis AG

Chapters

Executive Summary
Anti-tuberculosis Therapeutics Market Overview
1. Anti-tuberculosis Therapeutics Market Definition & Scope
2. Currency, Year and Forecasts Overview
3. Anti-tuberculosis Therapeutics Market 360° Synopsis: Overview
Anti-tuberculosis Therapeutics Industry Analysis
1. Industry Value Chain Analysis
2. Key Companies at each phase of Value Chain
3. Industry Trend Analysis
Anti-tuberculosis Therapeutics Market Analysis
1. Drives, Restraints, Opportunities and Challenges Impact Analysis
2. Porter’s Five Force Model Analysis
3. PESTLE Analysis
4. BPS Analysis
5. Anti-tuberculosis Therapeutics Market Key Innovation & Trends
6. Pricing Patterns (Company & Product Type)
Anti-tuberculosis Therapeutics Market: Drug Class
1. Introduction
2. Amynoglycosides: Market Trends, Size, and Forecast (2017-2026)
3. Bedaquiline: Market Trends, Size, and Forecast (2017-2026)
4. Cyclic Peptides: Market Trends, Size, and Forecast (2017-2026)
5. Ethambutol: Market Trends, Size, and Forecast (2017-2026)
6. Fluoroquinolones: Market Trends, Size, and Forecast (2017-2026)
7. Isoniazid: Market Trends, Size, and Forecast (2017-2026)
8. Other Drug Classes: Market Trends, Size, and Forecast (2017-2026)
9. Pyrazinamide: Market Trends, Size, and Forecast (2017-2026)
10. Rifampin: Market Trends, Size, and Forecast (2017-2026)
11. Thioamides: Market Trends, Size, and Forecast (2017-2026)
Anti-tuberculosis Therapeutics Market: End User
1. Introduction
2. Government Agencies: Market Trends, Size, and Forecast (2017-2026)
3. Hospitals and Clinics: Market Trends, Size, and Forecast (2017-2026)
4. Non Profit Organizations: Market Trends, Size, and Forecast (2017-2026)
5. Other End Users: Market Trends, Size, and Forecast (2017-2026)
Global Analysis
1. Global Anti-tuberculosis Therapeutics Market, By Region, Y-O-Y Growth Analysis
  1. Introduction
  2. North America: Market Trends, Size, and Forecast (2017-2026)
  3. Europe: Market Trends, Size, and Forecast (2017-2026)
  4. Asia-Pacific: Market Trends, Size, and Forecast (2017-2026)
  5. Latin America: Market Trends, Size, and Forecast (2017-2026)
  6. Middle East & Africa: Market Trends, Size, and Forecast (2017-2026)
North America Analysis
1. North America Anti-tuberculosis Therapeutics Market, By Country, Y-O-Y Growth Analysis
  1. Introduction
  2. United States: Market Trends, Size, and Forecast (2017-2026)
    1. Introduction
    2. United States Anti-tuberculosis Therapeutics Market: Drug Class
    3. United States Anti-tuberculosis Therapeutics Market: End User
  3. Canada: Market Trends, Size, and Forecast (2017-2026)
    1. Introduction
    2. Canada Anti-tuberculosis Therapeutics Market: Drug Class
    3. Canada Anti-tuberculosis Therapeutics Market: End User
2. North America Anti-tuberculosis Therapeutics Market, By Drug Class, Y-O-Y Growth Analysis
  1. Introduction
  2. Amynoglycosides: Market Trends, Size, and Forecast (2017-2026)
  3. Bedaquiline: Market Trends, Size, and Forecast (2017-2026)
  4. Cyclic Peptides: Market Trends, Size, and Forecast (2017-2026)
  5. Ethambutol: Market Trends, Size, and Forecast (2017-2026)
  6. Fluoroquinolones: Market Trends, Size, and Forecast (2017-2026)
  7. Isoniazid: Market Trends, Size, and Forecast (2017-2026)
  8. Other Drug Classes: Market Trends, Size, and Forecast (2017-2026)
  9. Pyrazinamide: Market Trends, Size, and Forecast (2017-2026)
  10. Rifampin: Market Trends, Size, and Forecast (2017-2026)
  11. Thioamides: Market Trends, Size, and Forecast (2017-2026)
3. North America Anti-tuberculosis Therapeutics Market, By End User, Y-O-Y Growth Analysis
  1. Introduction
  2. Government Agencies: Market Trends, Size, and Forecast (2017-2026)
  3. Hospitals and Clinics: Market Trends, Size, and Forecast (2017-2026)
  4. Non Profit Organizations: Market Trends, Size, and Forecast (2017-2026)
  5. Other End Users: Market Trends, Size, and Forecast (2017-2026)
Europe Analysis
1. Europe Anti-tuberculosis Therapeutics Market, By Country, Y-O-Y Growth Analysis
  1. Introduction
  2. Germany: Market Trends, Size, and Forecast (2017-2026)
    1. Introduction
    2. Germany Anti-tuberculosis Therapeutics Market: Drug Class
    3. Germany Anti-tuberculosis Therapeutics Market: End User
  3. United Kingdom: Market Trends, Size, and Forecast (2017-2026)
    1. Introduction
    2. United Kingdom Anti-tuberculosis Therapeutics Market: Drug Class
    3. United Kingdom Anti-tuberculosis Therapeutics Market: End User
  4. France: Market Trends, Size, and Forecast (2017-2026)
    1. Introduction
    2. France Anti-tuberculosis Therapeutics Market: Drug Class
    3. France Anti-tuberculosis Therapeutics Market: End User
  5. Spain: Market Trends, Size, and Forecast (2017-2026)
    1. Introduction
    2. Spain Anti-tuberculosis Therapeutics Market: Drug Class
    3. Spain Anti-tuberculosis Therapeutics Market: End User
  6. Russia: Market Trends, Size, and Forecast (2017-2026)
    1. Introduction
    2. Russia Anti-tuberculosis Therapeutics Market: Drug Class
    3. Russia Anti-tuberculosis Therapeutics Market: End User
  7. Italy: Market Trends, Size, and Forecast (2017-2026)
    1. Introduction
    2. Italy Anti-tuberculosis Therapeutics Market: Drug Class
    3. Italy Anti-tuberculosis Therapeutics Market: End User
  8. Rest of Europe: Market Trends, Size, and Forecast (2017-2026)
    1. Introduction
    2. Rest of Europe Anti-tuberculosis Therapeutics Market: Drug Class
    3. Rest of Europe Anti-tuberculosis Therapeutics Market: End User
2. Europe Anti-tuberculosis Therapeutics Market, By Drug Class, Y-O-Y Growth Analysis
  1. Introduction
  2. Amynoglycosides: Market Trends, Size, and Forecast (2017-2026)
  3. Bedaquiline: Market Trends, Size, and Forecast (2017-2026)
  4. Cyclic Peptides: Market Trends, Size, and Forecast (2017-2026)
  5. Ethambutol: Market Trends, Size, and Forecast (2017-2026)
  6. Fluoroquinolones: Market Trends, Size, and Forecast (2017-2026)
  7. Isoniazid: Market Trends, Size, and Forecast (2017-2026)
  8. Other Drug Classes: Market Trends, Size, and Forecast (2017-2026)
  9. Pyrazinamide: Market Trends, Size, and Forecast (2017-2026)
  10. Rifampin: Market Trends, Size, and Forecast (2017-2026)
  11. Thioamides: Market Trends, Size, and Forecast (2017-2026)
3. Europe Anti-tuberculosis Therapeutics Market, By End User, Y-O-Y Growth Analysis
  1. Introduction
  2. Government Agencies: Market Trends, Size, and Forecast (2017-2026)
  3. Hospitals and Clinics: Market Trends, Size, and Forecast (2017-2026)
  4. Non Profit Organizations: Market Trends, Size, and Forecast (2017-2026)
  5. Other End Users: Market Trends, Size, and Forecast (2017-2026)
Asia-Pacific Analysis
1. Asia-Pacific Anti-tuberculosis Therapeutics Market, By Country, Y-O-Y Growth Analysis
  1. Introduction
  2. China: Market Trends, Size, and Forecast (2017-2026)
    1. Introduction
    2. China Anti-tuberculosis Therapeutics Market: Drug Class
    3. China Anti-tuberculosis Therapeutics Market: End User
  3. Japan: Market Trends, Size, and Forecast (2017-2026)
    1. Introduction
    2. Japan Anti-tuberculosis Therapeutics Market: Drug Class
    3. Japan Anti-tuberculosis Therapeutics Market: End User
  4. India: Market Trends, Size, and Forecast (2017-2026)
    1. Introduction
    2. India Anti-tuberculosis Therapeutics Market: Drug Class
    3. India Anti-tuberculosis Therapeutics Market: End User
  5. Southeast Asia: Market Trends, Size, and Forecast (2017-2026)
    1. Introduction
    2. Southeast Asia Anti-tuberculosis Therapeutics Market: Drug Class
    3. Southeast Asia Anti-tuberculosis Therapeutics Market: End User
  6. Australia & New Zealand: Market Trends, Size, and Forecast (2017-2026)
    1. Introduction
    2. Australia & New Zealand Anti-tuberculosis Therapeutics Market: Drug Class
    3. Australia & New Zealand Anti-tuberculosis Therapeutics Market: End User
  7. Rest of Asia-Pacific: Market Trends, Size, and Forecast (2017-2026)
    1. Introduction
    2. Rest of Asia-Pacific Anti-tuberculosis Therapeutics Market: Drug Class
    3. Rest of Asia-Pacific Anti-tuberculosis Therapeutics Market: End User
2. Asia-Pacific Anti-tuberculosis Therapeutics Market, By Drug Class, Y-O-Y Growth Analysis
  1. Introduction
  2. Amynoglycosides: Market Trends, Size, and Forecast (2017-2026)
  3. Bedaquiline: Market Trends, Size, and Forecast (2017-2026)
  4. Cyclic Peptides: Market Trends, Size, and Forecast (2017-2026)
  5. Ethambutol: Market Trends, Size, and Forecast (2017-2026)
  6. Fluoroquinolones: Market Trends, Size, and Forecast (2017-2026)
  7. Isoniazid: Market Trends, Size, and Forecast (2017-2026)
  8. Other Drug Classes: Market Trends, Size, and Forecast (2017-2026)
  9. Pyrazinamide: Market Trends, Size, and Forecast (2017-2026)
  10. Rifampin: Market Trends, Size, and Forecast (2017-2026)
  11. Thioamides: Market Trends, Size, and Forecast (2017-2026)
3. Asia-Pacific Anti-tuberculosis Therapeutics Market, By End User, Y-O-Y Growth Analysis
  1. Introduction
  2. Government Agencies: Market Trends, Size, and Forecast (2017-2026)
  3. Hospitals and Clinics: Market Trends, Size, and Forecast (2017-2026)
  4. Non Profit Organizations: Market Trends, Size, and Forecast (2017-2026)
  5. Other End Users: Market Trends, Size, and Forecast (2017-2026)
Middle East & Africa Analysis
1. Middle East & Africa Anti-tuberculosis Therapeutics Market, By Country, Y-O-Y Growth Analysis
  1. Introduction
  2. Middle East: Market Trends, Size, and Forecast (2017-2026)
    1. Introduction
    2. Middle East Anti-tuberculosis Therapeutics Market: Drug Class
    3. Middle East Anti-tuberculosis Therapeutics Market: End User
  3. Africa: Market Trends, Size, and Forecast (2017-2026)
    1. Introduction
    2. Africa Anti-tuberculosis Therapeutics Market: Drug Class
    3. Africa Anti-tuberculosis Therapeutics Market: End User
  4. Rest of Middle East & Africa: Market Trends, Size, and Forecast (2017-2026)
    1. Introduction
    2. Rest of Middle East & Africa Anti-tuberculosis Therapeutics Market: Drug Class
    3. Rest of Middle East & Africa Anti-tuberculosis Therapeutics Market: End User
2. Middle East & Africa Anti-tuberculosis Therapeutics Market, By Drug Class, Y-O-Y Growth Analysis
  1. Introduction
  2. Amynoglycosides: Market Trends, Size, and Forecast (2017-2026)
  3. Bedaquiline: Market Trends, Size, and Forecast (2017-2026)
  4. Cyclic Peptides: Market Trends, Size, and Forecast (2017-2026)
  5. Ethambutol: Market Trends, Size, and Forecast (2017-2026)
  6. Fluoroquinolones: Market Trends, Size, and Forecast (2017-2026)
  7. Isoniazid: Market Trends, Size, and Forecast (2017-2026)
  8. Other Drug Classes: Market Trends, Size, and Forecast (2017-2026)
  9. Pyrazinamide: Market Trends, Size, and Forecast (2017-2026)
  10. Rifampin: Market Trends, Size, and Forecast (2017-2026)
  11. Thioamides: Market Trends, Size, and Forecast (2017-2026)
3. Middle East & Africa Anti-tuberculosis Therapeutics Market, By End User, Y-O-Y Growth Analysis
  1. Introduction
  2. Government Agencies: Market Trends, Size, and Forecast (2017-2026)
  3. Hospitals and Clinics: Market Trends, Size, and Forecast (2017-2026)
  4. Non Profit Organizations: Market Trends, Size, and Forecast (2017-2026)
  5. Other End Users: Market Trends, Size, and Forecast (2017-2026)
Latin America Analysis
1. Latin America Anti-tuberculosis Therapeutics Market, By Country, Y-O-Y Growth Analysis
  1. Introduction
  2. Brazil: Market Trends, Size, and Forecast (2017-2026)
    1. Introduction
    2. Brazil Anti-tuberculosis Therapeutics Market: Drug Class
    3. Brazil Anti-tuberculosis Therapeutics Market: End User
  3. Argentina: Market Trends, Size, and Forecast (2017-2026)
    1. Introduction
    2. Argentina Anti-tuberculosis Therapeutics Market: Drug Class
    3. Argentina Anti-tuberculosis Therapeutics Market: End User
  4. Mexico: Market Trends, Size, and Forecast (2017-2026)
    1. Introduction
    2. Mexico Anti-tuberculosis Therapeutics Market: Drug Class
    3. Mexico Anti-tuberculosis Therapeutics Market: End User
  5. Colombia: Market Trends, Size, and Forecast (2017-2026)
    1. Introduction
    2. Colombia Anti-tuberculosis Therapeutics Market: Drug Class
    3. Colombia Anti-tuberculosis Therapeutics Market: End User
  6. Rest of Latin America: Market Trends, Size, and Forecast (2017-2026)
    1. Introduction
    2. Rest of Latin America Anti-tuberculosis Therapeutics Market: Drug Class
    3. Rest of Latin America Anti-tuberculosis Therapeutics Market: End User
2. Latin America Anti-tuberculosis Therapeutics Market, By Drug Class, Y-O-Y Growth Analysis
  1. Introduction
  2. Amynoglycosides: Market Trends, Size, and Forecast (2017-2026)
  3. Bedaquiline: Market Trends, Size, and Forecast (2017-2026)
  4. Cyclic Peptides: Market Trends, Size, and Forecast (2017-2026)
  5. Ethambutol: Market Trends, Size, and Forecast (2017-2026)
  6. Fluoroquinolones: Market Trends, Size, and Forecast (2017-2026)
  7. Isoniazid: Market Trends, Size, and Forecast (2017-2026)
  8. Other Drug Classes: Market Trends, Size, and Forecast (2017-2026)
  9. Pyrazinamide: Market Trends, Size, and Forecast (2017-2026)
  10. Rifampin: Market Trends, Size, and Forecast (2017-2026)
  11. Thioamides: Market Trends, Size, and Forecast (2017-2026)
3. Latin America Anti-tuberculosis Therapeutics Market, By End User, Y-O-Y Growth Analysis
  1. Introduction
  2. Government Agencies: Market Trends, Size, and Forecast (2017-2026)
  3. Hospitals and Clinics: Market Trends, Size, and Forecast (2017-2026)
  4. Non Profit Organizations: Market Trends, Size, and Forecast (2017-2026)
  5. Other End Users: Market Trends, Size, and Forecast (2017-2026)
Anti-tuberculosis Therapeutics Market: Company Analysis
1. Introduction
2. Lupin Limited
  1. Overview
  2. Business Portfolio
  3. Product Portfolio
  4. Key Brands Insights
  5. Company SWOT & Strategic Analysis
  6. Company Financials
  7. Analyst Insights
3. Macleods Pharmaceuticals Ltd
4. Otsuka Pharmaceutical Co. Ltd
5. Johnson and Johnson
6. Pfizer Inc.
7. Novartis AG
Anti-tuberculosis Therapeutics Market: Competitive Analysis
1. Strategic Dashboard of Top Market Players
2. Companies Deals (Mergers, Partnerships, Acquisitions, JVs)
3. Expansion Areas (Based on Company Analysis)
4. Market Share Analysis
Anti-tuberculosis Therapeutics Market: Distribution Channel Analysis
1. Distributor Type Analysis
2. Major Distributors (Key Countries)
3. Future Growth Prospects
Industry & Analysts Insights forSuccess
Research Methodology
Appendix
1. List of Tables
2. List of Figures
3. Available Customizations
4. Related Reports